At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Engensis (VM202)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single Center, Open Label, Repeat Intramuscular Administration, 270 Days, Phase I/2a Clinical Trial to Evaluate Safety, Tolerability of Investigational Product (Engensis: VM202) With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)
In Brief
A Phase 2 clinical trial evaluating Engensis (VM202) for CMT. Completed, enrolled 12 participants across 1 site.
Detailed Summary
To assess the safety and tolerability of the investigational product Engensis (VM202) injected in the weakened lower limb muscles of CMT1A patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCMT
CountriesSouth Korea
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartSep 2020
Primary CompletionSep 2021
Study CompletionFeb 2022
First PostedMay 2022
TodayJul 2026
First PostedMay 4, 2022
Enrollment StartSep 21, 2020
Primary CompletionSep 9, 2021
Study CompletionFeb 22, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 4.2 years ago
Interventions
Engensis (VM202)biological
Intramuscular injections